Aller au contenu principal
← Tous les financements vérifiés
Tier AUS

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)

National Institutes of Health

Connectez-vous et complétez votre Funding Passport pour voir si vous êtes admissible — un verdict transparent, fondé sur des règles, pas une boîte noire.

Se connecter

À propos de cette possibilité

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies", or other biospecimens as described in this NOFO. Extramural research funded under this NOFO may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for "liquid biopsies", tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.

Documents requis

La source officielle n'indique pas de documents précis ici — vérifiez les exigences avant de postuler.

Source et traçabilité de vérification

Première collecte
20 novembre 2026
Dernière vérification
20 novembre 2026
Empreinte du contenu
683a0e6ae17b3ee5…